{"filing":{"accession_number":"0001493152-26-026953","cik":"0001610820","ticker":"BCTXZ","company_name":"BriaCell Therapeutics Corp.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226026953/form8-k.htm"},"events":[{"id":7238,"run_id":6352,"accession_number":"0001493152-26-026953","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"BriaCell entered into a Placement Agency Agreement on May 31, 2026, to issue and sell 1,449,300 common shares at $3.25 per share, raising $4.71 million in gross proceeds. The offering closed on June 2, 2026. Additionally, the company issued 72,465 warrants to the placement agent as compensation. This is a registered direct offering of equity securities that dilutes existing shareholders and represents a material capital-raising event for the company.","company_name":"BriaCell Therapeutics Corp.","ticker":"BCTXZ","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":4067,"accession_number":"0001493152-26-026953","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BriaCell entered into a Placement Agency Agreement on May 31, 2026, to issue and sell 1,449,300 common shares at $3.25 per share, raising $4.71 million in gross proceeds. The offering closed on June 2, 2026. Additionally, the company issued 72,465 warrants to the placement agent as compensation. This is a registered direct offering of equity securities that dilutes existing shareholders and represents a material capital-raising event for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:45:25.250030+00:00","company_name":"BriaCell Therapeutics Corp.","ticker":"BCTXZ","filing_date":"2026-06-03"}]}